These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33683934)

  • 1. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    J Urol; 2021 Jul; 206(1):69-79. PubMed ID: 33683934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.
    Chinea FM; Lyapichev K; Epstein JI; Kwon D; Smith PT; Pollack A; Cote RJ; Kryvenko ON
    Oncotarget; 2017 Mar; 8(13):20802-20812. PubMed ID: 28160549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
    Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis.
    Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Saad F; Chun FK; Shariat SF; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Int J Urol; 2018 Nov; 25(11):929-936. PubMed ID: 30146729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries.
    Wenzel M; Collà Ruvolo C; Nocera L; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Graefen M; Becker A; Mandel P; Chun FKH; Karakiewicz PI
    Cancer Epidemiol; 2021 Oct; 74():101994. PubMed ID: 34364187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial and ethnic disparities in robot-assisted radical prostatectomy: testing the physician-level segregated and differential treatment hypotheses.
    Mao J; Genkinger JM; Rundle AG; Wright JD; Insaf TZ; Schymura MJ; Hu JC; Tehranifar P
    JNCI Cancer Spectr; 2024 Jul; 8(4):. PubMed ID: 39051676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
    Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
    World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
    Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
    Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
    Lichtensztajn DY; Leppert JT; Brooks JD; Shah SA; Sieh W; Chung BI; Gomez SL; Cheng I
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1353-1360. PubMed ID: 30442735
    [No Abstract]   [Full Text] [Related]  

  • 11. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
    Lediju O; Ikuemonisan J; Salami SS; Adejoro O
    J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.
    Maurice MJ; Sundi D; Schaeffer EM; Abouassaly R
    J Urol; 2017 Mar; 197(3 Pt 1):627-631. PubMed ID: 27582435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Würnschimmel C; Wenzel M; Chierigo F; Flammia RS; Tian Z; Saad F; Briganti A; Shariat SF; Suardi N; Terrone C; Gallucci M; Chun FK; Tilki D; Graefen M; Karakiewicz PI
    Int J Urol; 2022 Jan; 29(1):17-24. PubMed ID: 34553428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
    J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach.
    Hanson HA; Martin C; O'Neil B; Leiser CL; Mayer EN; Smith KR; Lowrance WT
    J Urol; 2019 Dec; 202(6):1209-1216. PubMed ID: 31246547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study.
    Katz JE; Chinea FM; Patel VN; Balise RR; Venkatramani V; Gonzalgo ML; Ritch C; Pollack A; Parekh DJ; Punnen S
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):533-538. PubMed ID: 29988097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE.
    Latini DM; Elkin EP; Cooperberg MR; Sadetsky N; Duchane J; Carroll PR
    Cancer; 2006 Feb; 106(4):789-95. PubMed ID: 16400651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.
    Suresh T; Sharma J; Goel S; Kovac E; Gao Q; Gartrell B
    Clin Genitourin Cancer; 2019 Apr; 17(2):139-144. PubMed ID: 30655076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates.
    Collà Ruvolo C; Stolzenbach LF; Nocera L; Deuker M; Mistretta FA; Luzzago S; Tian Z; Longo N; Graefen M; Chun FKH; Saad F; Briganti A; De Cobelli O; Mirone V; Karakiewicz PI
    Urol Oncol; 2021 Jan; 39(1):74.e1-74.e7. PubMed ID: 32950397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.